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Background:  It is well documented that patients with AF may not provide reliable data on the frequency and duration of their paroxysms. The aim 
of this prospective observational study was to identify Responders to ablation through continuous subcutaneous monitoring for 1 year after ablation 
in patients with paroxysmal atrial fibrillation (PAF) or persistent AF (PersAF).
Methods:  Patients with symptomatic drug refractory AF were enrolled. Real-time three-dimensional (3D) left atrium maps were reconstructed 
by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc., Diamond Bar, CA, USA). The ipsilateral left and right pulmonary veins 
(PVs) were encircled in 1 lesion line by circumferential PV isolation. All patients were implanted with Reveal XT (Medtronic Inc.) for continuous AF 
monitoring and data collected every month during the 12-month follow-up.
Results:  We enrolled 129 patients (56 ± 9 years, 102 males), all of whom were followed-up for 12 months after the last ablation procedure: 58 
(45%) had a history of PersAF. After only 1 ablation procedure, 76 (59%) of the 129 patients were AF-free at 12-month: 48 out of 71 (68%) in the PAF 
group and 28 out of 58 (48%) in the PersAF group. After 1 or more ablation procedures, 94 (73%) of the 129 patients were AF-free 12 months after 
the last procedure: 57 out of 71 (80%) in the PAF group and 37 out of 58 (64%) in the PersAF group.
Conclusions:  Ablation is highly effective in treating AF, as assessed through detailed 1-year continuous monitoring: success rate is higher in PAF 
than in PersAF patients. The use of subcutaneous monitors is a valuable means of identifying responders and nonresponders, and can potentially 
guide antiarrhythmic and antithrombotic therapies.
